The differential effects of recombinant brain natriuretic peptide, nitroglycerine and dihydralazine on systemic oxygen delivery and gastric mucosal microvascular oxygenation in dogs.

Anaesthesia
L A SchwarteO Picker

Abstract

Brain natriuretic peptide has vasodilatory properties and may thus increase splanchnic perfusion and oxygenation. We compared the effects of recombinant brain natriuretic peptide on gastric mucosal microvascular haemoglobin oxygenation (reflectance spectrophotometry) and systemic variables with those of equi-hypotensive doses of two other vasodilators (nitroglycerine and dihydralazine). Chronically instrumented, healthy dogs were randomly allocated to receive on different days, one of the three drugs (nitroglycerine and dihydralazine doses titrated to reduce mean arterial pressure by ∼20%). Brain natriuretic peptide significantly increased gastric mucosal microvascular haemoglobin oxygenation selectively, i.e. without concomitant haemodynamic effects. In contrast, the other vasodilators either did not increase gastric mucosal microvascular haemoglobin oxygenation at all (nitroglycerine), or did so only with marked increases in other systemic haemodynamic variables (dihydralazine). Our data suggest a potential role of recombinant brain natriuretic peptide selectively for increasing microvascular mucosal oxygenation. Studies are required to extend these findings to the clinical setting.

References

Mar 3, 1988·Nature·T SudohH Matsuo
Dec 1, 1983·The American Journal of Medicine·M J MillerL J Rubin
May 29, 1998·American Journal of Respiratory and Critical Care Medicine·B Temmesfeld-WollbrückF Grimminger
Feb 24, 2001·Shock·H T HassounF A Moore
May 18, 2001·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·P O CarlssonL Jansson
Sep 5, 2002·Intensive Care Medicine·Mattijn Buwalda, Can Ince
Nov 9, 2002·Lancet·Peter E SpronkDurk F Zandstra
May 10, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Kim van der ZanderPeter W de Leeuw
Jun 10, 2003·Critical Care Medicine·John W Severinghaus
Mar 17, 2005·British Journal of Anaesthesia·H BerkenstadtA Perel
Mar 8, 2006·Critical Care Medicine·Rene SchmidtBenedikt H J Pannen
May 10, 2007·Drugs·Christian-Serge Degoute
Jan 26, 2008·Journal of Applied Physiology·Bradley J BehnkeMichael D Delp
Jun 10, 2008·Recent Patents on Cardiovascular Drug Discovery·Marek Jankowski
Aug 8, 2008·Current Opinion in Clinical Nutrition and Metabolic Care·Anja SandekStephan von Haehling
Mar 12, 2011·Intensive Care Medicine·Thomas W L Scheeren

❮ Previous
Next ❯

Citations

Apr 15, 2016·World Journal of Gastroenterology : WJG·Quan-Jun DengYong-Yu Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.